Literature DB >> 16716823

Pleural disease in lymphangioleiomyomatosis.

Khalid F Almoosa1, Francis X McCormack, Steven A Sahn.   

Abstract

Pleural disease is a common complication of lymphangioleiomyomatosis (LAM). The incidence and recurrence rates of secondary spontaneous pneumothorax in LAM are the highest among chronic pulmonary disorders. Most patients have at least one pneumothorax before LAM is diagnosed, and pneumothorax is often the sentinel event that leads to the diagnosis. Although early, definitive treatment for recurrent pneumothorax by pleurodesis is recommended, the failure rate for chemical and surgical approaches is high. Chylothorax occurs owing to obstruction of lymphatics by proliferating smooth muscle cells and often requires pleurodesis to control expanding and recurrent effusions. Because of the rarity of the LAM, few data exist on whether the occurrence of pleural complications in LAM accelerates functional decline or portends a worse prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 16716823     DOI: 10.1016/j.ccm.2006.01.005

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  11 in total

Review 1.  Unusual causes of pneumothorax.

Authors:  Daniel R Ouellette; Scott Parrish; Robert F Browning; J Francis Turner; Konstantinos Zarogoulidis; Ioanna Kougioumtzi; Georgios Dryllis; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Theodora Tsiouda; Athanasios Madesis; Theodoros Karaiskos; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  The Genetics of Pneumothorax.

Authors:  Philip M Boone; Rachel M Scott; Stefan J Marciniak; Elizabeth P Henske; Benjamin A Raby
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

3.  Multiple pneumothoraces during second and third trimesters as first presentation of lymphangioleiomyomatosis.

Authors:  Ruth McCartney; Nicola Facey; George Chalmers; Alan Mathers; Fiona Roberts; Gill Irvine; Kenneth Anderson
Journal:  Obstet Med       Date:  2009-05-22

Review 4.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

5.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

6.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

7.  Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis.

Authors:  Riffat Meraj; Kathryn A Wikenheiser-Brokamp; Lisa R Young; Sue Byrnes; Francis X McCormack
Journal:  Front Med       Date:  2012-12-07       Impact factor: 4.592

8.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

Review 9.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

10.  Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going.

Authors:  Angelo M Taveira-Dasilva; Wendy K Steagall; Joel Moss
Journal:  F1000 Med Rep       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.